EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord

Sing-Ong Lee, Yaswanth Kuthati iD, Wei-Hsiu Huang, Chih-Shung Wong

Cells · 08.11.2024 · 13 (22) · 1857

DOI: 10.3390/cells13221857 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 08.11.2024. Verfasst von Sing-Ong Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Cathay General Hospital, Taipei 106, Taiwan. Hauptthemen laut MEDLINE: Rats, Wistar, Diabetic Neuropathies, Spinal Cord, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology (Taiwan), Cathay research grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide 1 (GLP-1) receptor agonists are frequently used to treat type 2 diabetes and obesity. Despite the development of several drugs for neuropathic pain management, their poor efficacy, tolerance, addiction potential, and side effects limit their usage. Teneligliptin, a DPP-4 inhibitor, has been shown to reduce spinal astrocyte activation and neuropathic pain caused by partial sciatic nerve transection. Additionally, we showed its capacity to improve the analgesic effects of morphine and reduce analgesic tolerance. Recent studies indicate that GLP-1 synthesized in the brain activates GLP-1 receptor signaling pathways, essential for neuroprotection and anti-inflammatory effects. Multiple in vitro and in vivo studies using preclinical models of neurodegenerative disorders have shown the anti-inflammatory properties associated with glucagon-like peptide-1 receptor (GLP-1R) activation. This study aimed to investigate the mechanism of antinociception and the effects of the GLP-1 agonist semaglutide (SEMA) on diabetic neuropathic pain in diabetic rats.

Methods

Male Wistar rats, each weighing between 300 and 350 g, were categorized into four groups: one non-diabetic sham group and three diabetic groups. The diabetic group received a single intraperitoneal injection of streptozotocin (STZ) at a dosage of 60 mg/kg to induce diabetic neuropathy. After 4 weeks of STZ injection, one diabetic group was given saline (vehicle), and the other two were treated with either 1× SEMA (1.44 mg/kg, orally) or 2× SEMA (2.88 mg/kg, orally). Following a 4-week course of oral drug treatment, behavioral, biochemical, and immunohistochemical analyses were carried out. The mechanical allodynia, thermal hyperalgesia, blood glucose, advanced glycation end products (AGEs), plasma HbA1C, and spinal inflammatory markers were evaluated.

Results

SEMA treatment significantly reduced both allodynia and hyperalgesia in the diabetic group. SEMA therapy had a limited impact on body weight restoration and blood glucose reduction. In diabetic rats, SEMA lowered the amounts of pro-inflammatory cytokines in the spinal cord and dorsal horn. It also lowered the activation of microglia and astrocytes in the dorsal horn. SEMA significantly reduced HbA1c and AGE levels in diabetic rats compared to the sham control group.

Conclusions

These results indicate SEMA’s neuroprotective benefits against diabetic neuropathic pain, most likely by reducing inflammation and oxidative stress by inhibiting astrocyte and microglial activity. Our findings suggest that we can repurpose GLP-1 agonists as potent anti-hyperalgesic and anti-inflammatory drugs to treat neuropathic pain without serious side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rats, WistarDiabetic NeuropathiesSpinal CordDiabetes Mellitus, ExperimentalGlucagon-Like PeptidesNeuralgiaAnimalsMaleRatsNeuroinflammatory DiseasesSemaglutide

Stichwörter der Autor:innen

GLP-1RASEMAastrocytesdiabetic neuropathic painmicrogliapro-inflammatory cytokines

Substanzen

Glucagon-Like PeptidesSemaglutide

Autor:innen und Institutionen

  • Department of Anesthesiology, Cathay General Hospital, Taipei 106, Taiwan.
  • Department of Health and Leisure Management, Yuanpei University of Medical Technology, Hsinchu City 306, Taiwan.
  • Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.

ORCID-Profile: Yaswanth Kuthati

Förderung

  • Ministry of Science and Technology (Taiwan)
  • Cathay research grant

Zitieren

APA

Lee, S. O., Kuthati, Y., Huang, W. H., & Wong, C. S. (2024). Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. Cells, 13(22), 1857. https://doi.org/10.3390/cells13221857

Vancouver

Lee SO, Kuthati Y, Huang WH, Wong CS. Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord. Cells. 2024;13(22):1857. doi:10.3390/cells13221857

BibTeX
@article{Lee2024,
  author = {Lee, Sing-Ong and Kuthati, Yaswanth and Huang, Wei-Hsiu and Wong, Chih-Shung},
  title = {Semaglutide Ameliorates Diabetic Neuropathic Pain by Inhibiting Neuroinflammation in the Spinal Cord},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {22},
  pages = {1857},
  doi = {10.3390/cells13221857}
}
Kostenlos starten →